The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Polymyxin B for the treatment of multidrug-resistant pathogens: a critical review
Open accessAbstract
Polymyxins have re-emerged in clinical practice owing to the dry antibiotic development pipeline and worldwide increasing prevalence of nosocomial infections caused by multidrug-resistant (MDR) Gram-negative bacteria. Polymyxin B and colistin (polymyxin E) have been ultimately considered as the last-resort treatment of such infections. Microbiological, pharmacokinetic, pharmacodynamic and clinical data available for polymyxin B are reviewed in this paper. Polymyxin B has rapid in vitro bactericidal activity against major MDR Gram-negative bacteria, such as Pseudomonas aeruginosa, Acinetobacter baumannii and Klebsiella pneumoniae. Acquired resistance to this agent is still rare among these pathogens. However, optimized dosage regimens are not known yet. Good clinical outcomes have been observed in the majority of the patients treated with intravenous polymyxin B in recent studies. However, these studies failed to provide definitive conclusions due to limitations of study design and additional clinical trials are required. Although combination therapy may be an attractive option based on some currently available in vitro data, clinical data supporting such recommendations are lacking. Since polymyxins will be increasingly used for the treatment of infections caused by MDR bacteria, clinical pharmacokinetic, pharmacodynamic and toxicodynamic studies underpinning the optimal use of these drugs are urgently required.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Infectious Diseases Society of America
Enders, J. F. (1969) · Journal of Infectious Diseases · doi:10.1093/infdis/119.3.317 · Cited by 3,286
Falagas, M. E., Kasiakou, S. K., & Saravolatz, L. D. (2005) · Clinical Infectious Diseases · doi:10.1086/429323 · Cited by 1,744
Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections
Li, J., Nation, R. L., Turnidge, J. D., Milne, R. W., Coulthard, K., Rayner, C. R., & Paterson, D. L. (2006) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(06)70580-1 · Cited by 1,388
Self-citationEmergence and resurgence of meticillin-resistant Staphylococcus aureus as a public-health threat
Grundmann, H., Aires-de-Sousa, M., Boyce, J., & Tiemersma, E. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68853-3 · Cited by 1,101
Toxicity of polymyxins: a systematic review of the evidence from old and recent studies
Falagas, M. E., & Kasiakou, S. K. (2006) · Critical Care · doi:10.1186/cc3995 · Cited by 828
Polymyxin and Related Peptide Antibiotics
Storm, D. R., Rosenthal, K. S., & Swanson, P. E. (1977) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.46.070177.003451 · Cited by 759
Mechanisms of Multidrug Resistance in Acinetobacter Species and Pseudomonas aeruginosa
Bonomo, R. A., & Szabo, D. (2006) · Clinical Infectious Diseases · doi:10.1086/504477 · Cited by 741
Evaluation of colistin as an agent against multi-resistant Gram-negative bacteria
Li, J., Nation, R. L., Milne, R. W., Turnidge, J. D., & Coulthard, K. (2005) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2004.10.001 · Cited by 571
Self-citationDaptomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infections
Steenbergen, J. N., Alder, J., Thorne, G. M., & Tally, F. P. (2005) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkh546 · Cited by 561
Heteroresistance to Colistin in Multidrug-Resistant Acinetobacter baumannii
Li, J., Rayner, C. R., Nation, R. L., Owen, R. J., Spelman, D., Tan, K. E., & Liolios, L. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00103-06 · Cited by 548
Self-citationPolymyxin B Sulfate and Colistin: Old Antibiotics for Emerging Multiresistant Gram-Negative Bacteria
Evans, M. E., Feola, D. J., & Rapp, R. P. (1999) · Annals of Pharmacotherapy · doi:10.1345/aph.18426 · Cited by 544
Capsule Polysaccharide Mediates Bacterial Resistance to Antimicrobial Peptides
Campos, M. A., Vargas, M. A., Regueiro, V., Llompart, C. M., Albertí, S., & Bengoechea, J. A. (2004) · Infection and Immunity · doi:10.1128/iai.72.12.7107-7114.2004 · Cited by 518
History of the development of azole derivatives
Maertens, J. A. (2004) · Clinical Microbiology and Infection · doi:10.1111/j.1470-9465.2004.00841.x · Cited by 475
Moskowitz, S. M., Ernst, R. K., & Miller, S. I. (2004) · Journal of Bacteriology · doi:10.1128/jb.186.2.575-579.2004 · Cited by 418
Pandrug-resistant Gram-negative bacteria: the dawn of the post-antibiotic era?
Falagas, M. E., & Bliziotis, I. A. (2007) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2006.12.012 · Cited by 393
Gales, A. C., Reis, A. O., & Jones, R. N. (2001) · Journal of Clinical Microbiology · doi:10.1128/jcm.39.1.183-190.2001 · Cited by 382
Colistin Methanesulfonate Is an Inactive Prodrug of Colistin against Pseudomonas aeruginosa
Bergen, P. J., Li, J., Rayner, C. R., & Nation, R. L. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00035-06 · Cited by 366
Self-citationLee, H., Hsu, F.-F., Turk, J., & Groisman, E. A. (2004) · Journal of Bacteriology · doi:10.1128/jb.186.13.4124-4133.2004 · Cited by 334
Livermore, D. M. (2004) · Clinical Microbiology and Infection · doi:10.1111/j.1465-0691.2004.1004.x · Cited by 314
Manikal, V. M., Landman, D., Saurina, G., Oydna, E., Lal, H., & Quale, J. (2000) · Clinical Infectious Diseases · doi:10.1086/313902 · Cited by 309
Bratu, S., Tolaney, P., Karumudi, U., Quale, J., Mooty, M., Nichani, S., & Landman, D. (2005) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dki175 · Cited by 307
Gales, A. C., Jones, R. N., & Sader, H. S. (2006) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2005.01351.x · Cited by 302
Antoniadou, A., Kontopidou, F., Poulakou, G., Koratzanis, E., Galani, I., Papadomichelakis, E., Kopterides, P., Souli, M., Armaganidis, A., & Giamarellou, H. (2007) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkl562 · Cited by 273
Pharmacodynamics of Polymyxin B against Pseudomonas aeruginosa
Tam, V. H., Schilling, A. N., Vo, G., Kabbara, S., Kwa, A. L., Wiederhold, N. P., & Lewis, R. E. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.9.3624-3630.2005 · Cited by 204
Ouderkirk, J. P., Nord, J. A., Turett, G. S., & Kislak, J. W. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.8.2659-2662.2003 · Cited by 188
In vitro pharmacodynamics of colistin against Acinetobacter baumannii clinical isolates
Owen, R. J., Li, J., Nation, R. L., & Spelman, D. (2007) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkl512 · Cited by 176
Self-citationWinfield, M. D., & Groisman, E. A. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0406038101 · Cited by 173
Helander, I. M., Kilpeläinen, I., & Vaara, M. (1994) · Molecular Microbiology · doi:10.1111/j.1365-2958.1994.tb00329.x · Cited by 170
The Vibrio cholerae ToxR-Regulated Porin OmpU Confers Resistance to Antimicrobial Peptides
Mathur, J., & Waldor, M. K. (2004) · Infection and Immunity · doi:10.1128/iai.72.6.3577-3583.2004 · Cited by 166
British Society for Antimicrobial Chemotherapy
(2019) · The Grants Register 2020 · doi:10.1057/978-1-349-95943-3_200 · Cited by 163
Gram-Negative Outer and Inner Membrane Models: Insertion of Cyclic Cationic Lipopeptides
Clausell, A., Garcia-Subirats, M., Pujol, M., Busquets, M. A., Rabanal, F., & Cajal, Y. (2007) · The Journal of Physical Chemistry B · doi:10.1021/jp064757+ · Cited by 159
Acid pH activation of the PmrA/PmrB two‐component regulatory system of Salmonella enterica
Perez, J. C., & Groisman, E. A. (2007) · Molecular Microbiology · doi:10.1111/j.1365-2958.2006.05512.x · Cited by 158
Falagas, M. E., Kasiakou, S. K., Tsiodras, S., & Michalopoulos, A. (2006) · Clinical Medicine & Research · doi:10.3121/cmr.4.2.138 · Cited by 158
Sobieszczyk, M. E. (2004) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkh369 · Cited by 147
Tan, C.-H., Li, J., & Nation, R. L. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01571-06 · Cited by 138
Self-citationLoutet, S. A., Flannagan, R. S., Kooi, C., Sokol, P. A., & Valvano, M. A. (2006) · Journal of Bacteriology · doi:10.1128/jb.188.6.2073-2080.2006 · Cited by 138
Li, J., Rayner, C. R., Nation, R. L., Deans, R., Boots, R. J., Widdecombe, N., Douglas, A., & Lipman, J. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.11.4814-4815.2005 · Cited by 133
Self-citationArroyo, L. A. R., García-Curiel, A., Pachón-Ibáñez, M. E., Llanos, A. C., Ruiz, M. T., Pachón, J., & Aznar, J. (2005) · Journal of Clinical Microbiology · doi:10.1128/jcm.43.2.903-905.2005 · Cited by 130
Brooks, R., Woods, C. W., Benjamin, Jr., & Rosenstein, N. E. (2006) · Clinical Infectious Diseases · doi:10.1086/504804 · Cited by 124
Tran, A. X., Whittimore, J. D., Wyrick, P. B., McGrath, S. C., Cotter, R. J., & Trent, M. S. (2006) · Journal of Bacteriology · doi:10.1128/jb.00146-06 · Cited by 109
Transcriptional Regulation of the 4-Amino-4-deoxy-L-arabinose Biosynthetic Genes in Yersinia pestis
Winfield, M. D., Latifi, T. N., & Groisman, E. A. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m413900200 · Cited by 108
Delgado, M. A., Mouslim, C., & Groisman, E. A. (2006) · Molecular Microbiology · doi:10.1111/j.1365-2958.2006.05069.x · Cited by 95
mig - 14 Is a Salmonella Gene That Plays a Role in Bacterial Resistance to Antimicrobial Peptides
Brodsky, I. E., Ernst, R. K., Miller, S. I., & Falkow, S. (2002) · Journal of Bacteriology · doi:10.1128/jb.184.12.3203-3213.2002 · Cited by 91
Quinupristin/dalfopristin and linezolid: where, when, which and whether to use?
Livermore, D. M. (2000) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/46.3.347 · Cited by 89
Holloway, K. P., Rouphael, N., Wells, J. B., King, M. D., & Blumberg, H. M. (2006) · Annals of Pharmacotherapy · doi:10.1345/aph.1h353 · Cited by 84
Pereira, G. H., Müller, P. R., & Levin, A. S. (2007) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2007.01.008 · Cited by 81
LABORATORY AND CLINICAL STUDIES OF POLYMYXIN B AND E 12
Pulaski, E. J., Baker, H. J., Rosenberg, M. L., & Connell, J. F. (1949) · Journal of Clinical Investigation · doi:10.1172/jci102134 · Cited by 42
Jones, R. N., Anderegg, T. R., & Swenson, J. M. (2005) · Journal of Clinical Microbiology · doi:10.1128/jcm.43.2.925-927.2005 · Cited by 42
Kroeger, L. A., Hovde, L. B., Mitropoulos, I. F., Schafer, J. A., & Rotschafer, J. C. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01433-06 · Cited by 26
Cited by
Antibiotic resistance in Pseudomonas aeruginosa: mechanisms and alternative therapeutic strategies
Pang, Z., Raudonis, R., Glick, B. R., Lin, T.-J., & Cheng, Z. (2019) · Biotechnology Advances · doi:10.1016/j.biotechadv.2018.11.013 · Cited by 2,306
The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria
Nordmann, P., Cuzon, G., & Naas, T. (2009) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(09)70054-4 · Cited by 1,579
Towards the sustainable discovery and development of new antibiotics
Miethke, M., Pieroni, M., Weber, T., Brönstrup, M., Hammann, P., Halby, L., Arimondo, P. B., Glaser, P., Aigle, B., Bode, H. B., et al. (2021) · Nature Reviews Chemistry · doi:10.1038/s41570-021-00313-1 · Cited by 1,151
Lee, C.-R., Lee, J. H., Park, M., Park, K. S., Bae, I. K., Kim, Y. B., Cha, C.-J., Jeong, B. C., & Lee, S. H. (2017) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2017.00055 · Cited by 1,016
Horcajada, J. P., Montero, M., Oliver, A., Sorlí, L., Luque, S., Gómez-Zorrilla, S., Benito, N., & Grau, S. (2019) · Clinical Microbiology Reviews · doi:10.1128/cmr.00031-19 · Cited by 961
Metadata
- Authors
- Zavascki, A. P., Goldani, L. Z., Li, J., & Nation, R. L.
- Venue
- Journal of Antimicrobial Chemotherapy
- Publisher
- Oxford University Press (OUP)
- Published
- 2007-10-03
- Volume
- 60
- Issue
- 6
- Pages
- 1206-1215
- ISSN
- 0305-7453 (ISSN-L)
- 1460-2091
- OpenAlex
- W2107050135
- Cited by
- 834
- References
- 49
- FWCI
- 11.98
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.